The future of myeloma treatment and the possibility of cure
In this video, Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the future treatment of myeloma…
Related Articles
PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, introduces the PHOEBUS study (NCT05762211), a Phase IIb trial investigating the use of MaaT003,…
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox, MbChB, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses an individualized approach to assessing potential risks of bone marrow…
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas, MD, University College London, London, UK, summarizes a talk on the role of donor lymphocyte infusion (DLI) in the post-allogenic stem cell transplant…
PTCy as GvHD prophylaxis: side effects, optimizing the dose, and the effect of dose-reduction
Rémy Duléry, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the main side effects associated with post-transplant cyclophosphamide (PTCy) as prophylaxis for graft-versus-host disease (GvHD) following…
Immune checkpoint inhibitors in MDS: the i4MDS consortium
Shahram Kordasti, MSc, MD, PhD, King’s College London, London, UK, shares his thoughts on the potential therapeutic capacity of immune checkpoint inhibitors (ICIs) in patients…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Combination approaches in AML and overcoming venetoclax resistance
Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, discusses promising combination approaches for overcoming venetoclax resistance in acute myeloid leukemia (AML). He mentions…
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox, MbChB, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses CRISPR-based autologous gene therapy for treating primary immunodeficiency disorders (PIDs).…
Immune checkpoint inhibitors in MDS: the i4MDS consortium
Shahram Kordasti, MSc, MD, PhD, King’s College London, London, UK, shares his thoughts on the potential therapeutic capacity of immune checkpoint inhibitors (ICIs) in patients…
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon, summarizes a talk on the current standard of care, outcomes, and unmet…